Unknown

Dataset Information

0

A bispecific glycopeptide spatiotemporally regulates tumor microenvironment for inhibiting bladder cancer recurrence.


ABSTRACT: Up to 75% of bladder cancer patients suffer from recurrence due to postoperative tumor implantation. However, clinically used Bacillus Calmette-Guerin (BCG) treatment failed to inhibit the recurrence. Here, we report a bispecific glycopeptide (bsGP) that simultaneously targets CD206 on tumor-associated macrophages (TAMs) and CXCR4 on tumor cells. bsGP repolarizes protumoral M2-like TAMs to antitumor M1-like that mediated cytotoxicity and T cell recruitment. Meanwhile, bsGP is cleaved by the MMP-2 enzyme to form nanostructure for the long-term inhibition of CXCR4 downstream signaling, resulting in reduced tumor metastasis and promoted T cell infiltration. In orthotopic bladder tumor models, bsGP reduced the postoperative recurrence rate to 22%. In parallel, the recurrence rates of 89 and 78% were treated by doxycycline and BCG used in clinic, respectively. Mechanistic studies reveal that bsGP reduces the matrix microenvironment barrier, increasing the spatially redirected CD8+ T cells to tumor cells. We envision that bis-targeting CD206 and CXCR4 may pave the way to inhibit tumor metastasis and recurrence.

SUBMITTER: An HW 

PROVIDER: S-EPMC9977173 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

A bispecific glycopeptide spatiotemporally regulates tumor microenvironment for inhibiting bladder cancer recurrence.

An Hong-Wei HW   Hou Da-Yong DY   Yang Jia J   Wang Zi-Qi ZQ   Wang Man-Di MD   Zheng Rui R   Zhang Ni-Yuan NY   Hu Xing-Jie XJ   Wang Zhi-Jia ZJ   Wang Lu L   Liu Di D   Hao Jun-Feng JF   Xu Wanhai W   Zhao Yuliang Y   Wang Hao H  

Science advances 20230301 9


Up to 75% of bladder cancer patients suffer from recurrence due to postoperative tumor implantation. However, clinically used Bacillus Calmette-Guerin (BCG) treatment failed to inhibit the recurrence. Here, we report a bispecific glycopeptide (bsGP) that simultaneously targets CD206 on tumor-associated macrophages (TAMs) and CXCR4 on tumor cells. bsGP repolarizes protumoral M2-like TAMs to antitumor M1-like that mediated cytotoxicity and T cell recruitment. Meanwhile, bsGP is cleaved by the MMP-  ...[more]

Similar Datasets

| S-EPMC8329301 | biostudies-literature
| S-EPMC8978677 | biostudies-literature
| S-EPMC10625065 | biostudies-literature
| S-EPMC3917779 | biostudies-literature
| S-EPMC10764810 | biostudies-literature
| S-EPMC11098120 | biostudies-literature
| S-EPMC11742431 | biostudies-literature
| S-EPMC8367065 | biostudies-literature
| S-EPMC8814447 | biostudies-literature
| S-EPMC8479184 | biostudies-literature